Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

被引：397

作者：

Antonarakis, Emmanuel S. ^{[1
]}

Lu, Changxue ^{[1
]}

Luber, Brandon ^{[1
]}

Wang, Hao ^{[1
]}

Chen, Yan ^{[1
]}

Zhu, Yezi ^{[1
]}

Silberstein, John L. ^{[1
]}

Taylor, Maritza N. ^{[1
]}

Maughan, Benjamin L. ^{[1
]}

Denmeade, Samuel R. ^{[1
]}

Pienta, Kenneth J. ^{[1
]}

Paller, Channing J. ^{[1
]}

Carducci, Michael A. ^{[1
]}

Eisenberger, Mario A. ^{[1
]}

Luo, Jun ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 19期

基金：

美国国家卫生研究院;

关键词：

TRIALS WORKING GROUP; RECOMMENDATIONS; DESIGN; AR-V7;

D O I：

10.1200/JCO.2016.70.1961

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abiraterone and enzalutamide in patients with castration-resistant prostate cancer (CRPC). Here, we expanded our cohort size to better characterize the prognostic significance of AR-V7 in this setting. Methods We prospectively enrolled 202 patients with CRPC starting abiraterone or enzalutamide and investigated the prognostic value of CTC detection (+ v -) and AR-V7 detection (+ v -) using a CTC-based AR-V7 mRNA assay. We examined >= 50% prostate-specific antigen (PSA) responses, PSA progression-free survival, clinical and radiologic progression-free survival, and overall survival. We constructed multivariable models adjusting for PSA, Gleason sum, number of prior hormone therapies, prior abiraterone or enzalutamide use, prior taxane use, presence of visceral metastases, and Eastern Cooperative Oncology Group score. We also separately examined the first-line and second-line novel hormonal therapy (NHT) settings. Results Median follow-up times were 15.0, 21.7, and 14.6 months for CTC-, CTC+/AR-V7- and CTC+/AR-V7+ patients, respectively. CTC+/AR-V7+ patients were more likely to have Gleason scores >= 8 (P = .05), metastatic disease at diagnosis (P = .01), higher PSA (P,.01), prior abiraterone or enzalutamide use (P =.03), prior taxane use (P = .02), and Eastern Cooperative Oncology Group >= 1 (P = .01). Outcomes for the overall cohort (and separately for the first-line and second-line NHT cohorts) were best for CTC-patients, intermediate for CTC+/AR-V7-patients, and worse for CTC+/AR-V7+ patients. These correlations remained significant in multivariable models. Conclusion This expanded analysis further characterizes the importance of CTC-based AR-V7 mRNA detection in predicting outcomes in patients with CRPC receiving first-and second-line NHT and, to the best of our knowledge, is the first to suggest that this assay be interpreted using three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+. J Clin Oncol 35: 2149-2156. (C) 2017 by American Society of Clinical Oncology

引用

页码：2149 / +

页数：9

共 13 条

[1]

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting [J].

Antonarakis, E. S. ;

Armstrong, A. J. ;

Dehm, S. M. ;

Luo, J. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (03) :231-241

[2]

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

[3]

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[4]

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer [J].

Bernemann, Christof ;

Schnoeller, Thomas J. ;

Luedeke, Manuel ;

Steinestel, Konrad ;

Boegemann, Martin ;

Schrader, Andres J. ;

Steinestel, Julie .

EUROPEAN UROLOGY, 2017, 71 (01) :1-3

[5]

de Bono JS, 1995, N ENGL J MED, V364

[6]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7]

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance [J].

Miyamoto, David T. ;

Zheng, Yu ;

Wittner, Ben S. ;

Lee, Richard J. ;

Zhu, Huili ;

Broderick, Katherine T. ;

Desai, Rushil ;

Fox, Douglas B. ;

Brannigan, Brian W. ;

Trautwein, Julie ;

Arora, Kshitij S. ;

Desai, Niyati ;

Dahl, Douglas M. ;

Sequist, Lecia V. ;

Smith, Matthew R. ;

Kapur, Ravi ;

Wu, Chin-Lee ;

Shioda, Toshi ;

Ramaswamy, Sridhar ;

Ting, David T. ;

Toner, Mehmet ;

Maheswaran, Shyamala ;

Haber, Daniel A. .

SCIENCE, 2015, 349 (6254) :1351-1356

[8]

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells [J].

Onstenk, Wendy ;

Sieuwerts, Anieta M. ;

Kraan, Jaco ;

Van, Mai ;

Nieuweboer, Annemieke J. M. ;

Mathijssen, Ron H. J. ;

Hamberg, Paul ;

Meulenbeld, Hielke J. ;

De Laere, Bram ;

Dirix, Luc Y. ;

van Soest, Robert J. ;

Lolkema, Martijn P. ;

Martens, John W. M. ;

van Weerden, Wytske M. ;

Jenster, Guido W. ;

Foekens, John A. ;

de Wit, Ronald ;

Sleijfer, Stefan .

EUROPEAN UROLOGY, 2015, 68 (06) :939-945

[9]

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group [J].

Scher, Howard I. ;

Halabi, Susan ;

Tannock, Ian ;

Morris, Michael ;

Sternberg, Cora N. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Higano, Celestia ;

Bubley, Glenn J. ;

Dreicer, Robert ;

Petrylak, Daniel ;

Kantoff, Philip ;

Basch, Ethan ;

Kelly, William Kevin ;

Figg, William D. ;

Small, Eric J. ;

Beer, Tomasz M. ;

Wilding, George ;

Martin, Alison ;

Hussain, Maha .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1148-1159

[10]

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer [J].

Scher, Howard I. ;

Lu, David ;

Schreiber, Nicole A. ;

Louw, Jessica ;

Graf, Ryon P. ;

Vargas, Hebert A. ;

Johnson, Ann ;

Jendrisak, Adam ;

Bambury, Richard ;

Danila, Daniel ;

McLaughlin, Brigit ;

Wahl, Justin ;

Greene, Stephanie B. ;

Heller, Glenn ;

Marrinucci, Dena ;

Fleisher, Martin ;

Dittamore, Ryan .

JAMA ONCOLOGY, 2016, 2 (11) :1441-1449

← 1 2 →